Dr. Suzette Sutherland

So that's a huge number, right? One third of the patients. And we're talking about something as serious as CIS. Exactly.

So that's a huge number, right? One third of the patients. And we're talking about something as serious as CIS. Exactly.

It is amazing having trained in the era before blue light and how we thought we were doing such a good job with our two RBTs. And now with the blue light, you see the residual tumor, as you said, that you miss. I mean, I didn't know until doing a little more research myself in anticipation of this podcast how high that number was.

It is amazing having trained in the era before blue light and how we thought we were doing such a good job with our two RBTs. And now with the blue light, you see the residual tumor, as you said, that you miss. I mean, I didn't know until doing a little more research myself in anticipation of this podcast how high that number was.

It is amazing having trained in the era before blue light and how we thought we were doing such a good job with our two RBTs. And now with the blue light, you see the residual tumor, as you said, that you miss. I mean, I didn't know until doing a little more research myself in anticipation of this podcast how high that number was.

And when you look at the recurrence rates or the residual tumor rate, I mean, as you said, sometimes this can be up to two thirds in some reports, but even how much of T1 disease versus T2 disease gets missed, you know, because the resection isn't done adequately enough just with white light. So up to 15 to almost 30%. So of the residual disease being T1 to T2.

And when you look at the recurrence rates or the residual tumor rate, I mean, as you said, sometimes this can be up to two thirds in some reports, but even how much of T1 disease versus T2 disease gets missed, you know, because the resection isn't done adequately enough just with white light. So up to 15 to almost 30%. So of the residual disease being T1 to T2.

And when you look at the recurrence rates or the residual tumor rate, I mean, as you said, sometimes this can be up to two thirds in some reports, but even how much of T1 disease versus T2 disease gets missed, you know, because the resection isn't done adequately enough just with white light. So up to 15 to almost 30%. So of the residual disease being T1 to T2.

So again, we know this totally changes the The prognosis of the patient, right, and what we're going to do next or what we should be advocating for next. I just wanted to make that point that when we look at the newer, I think they came out in 2024, yeah, just last spring, the AUA-SUO guidelines concerning this.

So again, we know this totally changes the The prognosis of the patient, right, and what we're going to do next or what we should be advocating for next. I just wanted to make that point that when we look at the newer, I think they came out in 2024, yeah, just last spring, the AUA-SUO guidelines concerning this.

So again, we know this totally changes the The prognosis of the patient, right, and what we're going to do next or what we should be advocating for next. I just wanted to make that point that when we look at the newer, I think they came out in 2024, yeah, just last spring, the AUA-SUO guidelines concerning this.

They actually say in patients with non-muscle invasive bladder cancer, we should be offering blue light cystoscopy. Now they make the caveat, you know, at the time of TURBT, the caveat is if available to enhance detection and decrease recurrence. So it's a moderate grade, grade B evidence strength. But again, they do put that word should in there as opposed to saying should. could, right?

They actually say in patients with non-muscle invasive bladder cancer, we should be offering blue light cystoscopy. Now they make the caveat, you know, at the time of TURBT, the caveat is if available to enhance detection and decrease recurrence. So it's a moderate grade, grade B evidence strength. But again, they do put that word should in there as opposed to saying should. could, right?

They actually say in patients with non-muscle invasive bladder cancer, we should be offering blue light cystoscopy. Now they make the caveat, you know, at the time of TURBT, the caveat is if available to enhance detection and decrease recurrence. So it's a moderate grade, grade B evidence strength. But again, they do put that word should in there as opposed to saying should. could, right?

So the data is pushing a little more towards or pointing towards the real potential, the benefits of this blue light imaging.

So the data is pushing a little more towards or pointing towards the real potential, the benefits of this blue light imaging.

So the data is pushing a little more towards or pointing towards the real potential, the benefits of this blue light imaging.

And then I guess to take it to another direction a little bit, these patients that have mixed, you know, low and high grade histology or uncommon variants, does it help to determine, you know, is it picked up by the uncommon variants as well so it can help to determine these more really high, high risk patients? Yes.

And then I guess to take it to another direction a little bit, these patients that have mixed, you know, low and high grade histology or uncommon variants, does it help to determine, you know, is it picked up by the uncommon variants as well so it can help to determine these more really high, high risk patients? Yes.

And then I guess to take it to another direction a little bit, these patients that have mixed, you know, low and high grade histology or uncommon variants, does it help to determine, you know, is it picked up by the uncommon variants as well so it can help to determine these more really high, high risk patients? Yes.